EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions — single center experience

Joanna Ewa Drozd-Sokołowska, Anna Waszczuk-Gajda, Jadwiga Dwilewicz-Trojaczek, Alicja Walesiak, Monika Krzyżanowska, Monika Paluszewska, Jolanta Wieczorek, Wiesław Wiktor-Jędrzejczak

Folia Medica Cracoviensia · 08.04.2021 · 53-64

DOI: 10.24425/fmc.2020.136204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Medica Cracoviensia, online erschienen am 08.04.2021. Verfasst von Joanna Ewa Drozd-Sokołowska und 7 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignancies of the hematopoietic system frequently are associated with severe cytopenias requiring transfusions of blood components. Refusal of blood components by Jehovah’s Witnesses (JW) produces challenges to treatment. In this report we describe the outcome of hematological malignancies of JW patients treated without transfusions. Altogether, eight JW, diagnosed 1994–2015, 6 (75%) females, the median age at diagnosis 40 years (range, 20–78), were included into the analysis. The diagnoses were: acute lymphoblastic leukemia (2, 25%), acute myeloid leukemia (2, 25%), non-Hodgkin’s lymphomas (4, 50%). One patient died without treatment while the remaining 7 patients received treatment, including imatinib in 1 patient with BCR-ABL1+ acute lymphoblastic leukemia. Five (62.5%) patients received erythropoiesis stimulating agents. Median hemoglobin concentration at diagnosis was 8.7 g/dL (range, 6.3–13.1), and it decreased to 3.2 g/dL (range, 2.6–9.3) during first-line treatment. Median platelet count at diagnosis was 52 × 109/L (range, 15–392). All patients became thrombocytopenic upon treatment reaching median platelet count 8 × 109/L (range, 2–85). Five patients developed respiratory failure. Anemia contributed substantially to the death of 3 out of 6 patients (50%). One patient (17%) developed central nervous system bleeding in the course of thrombocytopenia. Objective response rate was 43%, with 29% complete remissions after first-line treatment. Despite the median overall survival of 15.3 months (95% CI, 0.2–52.2), all but one acute leukemia patients succumbed shortly after the diagnosis. To conclude, the outcome of JW treated because of hematological malignancies without blood transfusions is very dismal, nevertheless, selected patients can obtain complete remissions. Anemia contributes significantly to the death of JW.

Zitieren

APA

Drozd-Sokołowska, J. E., Waszczuk-Gajda, A., Dwilewicz-Trojaczek, J., Walesiak, A., Krzyżanowska, M., Paluszewska, M., Wieczorek, J., & Wiktor-Jędrzejczak, W. (2021). Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions — single center experience. Folia Medica Cracoviensia, 53-64. https://doi.org/10.24425/fmc.2020.136204

Vancouver

Drozd-Sokołowska JE, Waszczuk-Gajda A, Dwilewicz-Trojaczek J, Walesiak A, Krzyżanowska M, Paluszewska M, et al. Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions — single center experience. Folia Medica Cracoviensia. 2021:53-64. doi:10.24425/fmc.2020.136204

BibTeX
@article{DrozdSokoowska2021,
  author = {Drozd-Sokołowska, Joanna Ewa and Waszczuk-Gajda, Anna and Dwilewicz-Trojaczek, Jadwiga and Walesiak, Alicja and Krzyżanowska, Monika and Paluszewska, Monika and Wieczorek, Jolanta and Wiktor-Jędrzejczak, Wiesław},
  title = {Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions — single center experience},
  journal = {Folia Medica Cracoviensia},
  year = {2021},
  pages = {53--64},
  doi = {10.24425/fmc.2020.136204}
}
Kostenlos starten →